Latest Investment News

Canadian Phosphate (ASX: CP8) is raising up to AUD 4.85 million via a renounceable rights issue at a 22% discount, aiming to accelerate development of its newly acquired Diamond Mountain Project in Utah and advance exploration in Canada.

Evion Group has increased the size of its second tranche placement, lifting total capital raised to A$7.24 million through the issue of over 241 million shares at 3 cents each. The second tranche awaits shareholder approval at a July meeting, including director participation and free attaching options.

Sequoia Financial Group has pushed back its interim dividend payment to 29 June 2026 due to unresolved court proceedings and negotiations over the sale of its InterPrac subsidiary. The Federal Court has set a tight timetable for filings on the Share Sale Agreement status, with a potential hearing in July.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Excite Technology Services lifted revenue by 74% to $21.3 million in FY26 but still recorded a $5.4 million loss, with auditors flagging material uncertainty over its ability to continue as a going concern.

Burger Fuel Group reported a 91.8% surge in net profit to NZD 1.97 million for FY26, driven by sales growth, reduced legal costs, and a one-off store sale gain, despite geopolitical headwinds in the Middle East.

Elanor Investors Group has called off its planned acquisition of Singapore-based Firmus Capital due to prolonged regulatory delays, while reaffirming its $125 million recapitalisation with Rockworth Capital Partners and seeking ASX trading reinstatement.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

ArborGen Holdings delivered its strongest revenue in five years with $68.2 million, driven by a 14% surge in Brazil and an 8% rise in adjusted EBITDA despite US market headwinds. The company’s focus on advanced genetics and operational efficiency underpins a confident FY27 outlook.

Booster Innovation Fund has trimmed its net asset value per unit to $1.47 following a $723,000 valuation adjustment driven by slower growth and capital raising dynamics in its portfolio.